(Q39207594)

10 September 2017

title

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies (English)

1 reference

10 September 2017

1 reference

1 reference

1 reference

2

Otto C Boerman

1 reference

10 September 2017

4

Wim J G Oyen

0 references

author name string

Sandra Heskamp

1

1 reference

10 September 2017

Janneke D M Molkenboer-Kuenen

3

1 reference

10 September 2017

Wim J G Oyen

4

1 reference

10 September 2017

Winette T A van der Graaf

5

1 reference

10 September 2017

Hanneke W M van Laarhoven

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

15 February 2013

1 reference

International Journal of Cancer

10 September 2017

published in

1 reference

10 September 2017

volume

133

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

307-314

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

10 September 2017

cites work

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells

21 January 2018

1 reference

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

21 January 2018

1 reference

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

21 January 2018

1 reference

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

21 January 2018

1 reference

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

21 January 2018

1 reference

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model

21 January 2018

1 reference

Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.

21 January 2018

1 reference

U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging

21 January 2018

1 reference

A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine

21 January 2018

1 reference

Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice

21 January 2018

1 reference

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

21 January 2018

1 reference

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib

21 January 2018

1 reference

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

21 January 2018

1 reference

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET

21 January 2018

1 reference

Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28046

1 reference

10 September 2017

1 reference